Lipum AB (publ)
556813-5999InactiveDeveloping first-in-class antibody drug candidate for chronic inflammatory diseases.
Clinical Stage Biopharmaceutical Companylipum.se
Översikt
- 5–9
- Anställda
- 750–999t SEK
- Omsättning
- 2010
- Grundat
Nyckelbeslutsfattare
Ola Sandborgh
CEO
Beskrivning
Lipum AB (publ) is a clinical-phase biopharmaceutical company focused on developing novel treatments for chronic inflammatory diseases. Their lead drug candidate is SOL-116, a humanized monoclonal antibody designed to offer a unique mechanism of action. SOL-116 targets the Bile Salt-Stimulated Lipas...
Taggar
HealthTech